Furthermore, the feasibility and safety of this approach is supported by previous phase I and phase II clinical trials using LX2931/LX3305 for the treatment of rheumatoid arthritis (NCT01417052 and NCT00903383); thus, opening the way for the repurposing of this drug or development of other S1P modulators as tumor vascular normalizing therapies for cancer patients. This evidence concerns the gene MBTPS1 and neoplasm.